What BIAL does

BIAL is a privately-held, family-controlled Portuguese pharmaceutical company founded in 1924 and headquartered in Trofa (S. Mamede do Coronado), Portugal, with approximately 800 employees and operations across 15 countries. The company focuses on discovering, developing, and commercializing proprietary prescription medicines in neurosciences and rare diseases, underpinned by an R&D investment of more than 20% of annual revenue. Its two core commercial assets are Acetato de Eslicarbazepina (marketed as Zebinix in Europe and Aptiom in the US), a once-daily third-generation anticonvulsant acting as a voltage-gated sodium channel blocker approved by EMA (2009) and FDA (2013), and Opicapona (Ongentys), a selective and reversible COMT inhibitor for end-of-dose motor fluctuations in Parkinson's disease approved across EU, USA, Japan, South Korea, and Australia.

The business operates a hybrid commercial model: direct sales forces via wholly-owned subsidiaries in core European markets (Portugal, Spain, Germany, Italy, Switzerland, UK) and selected international markets (USA, Angola, Côte d'Ivoire, Argentina), supplemented by licensing partnerships in Japan, the USA, Canada, China, and South Korea. BIAL manufactures at a Trofa facility with FDA approval and 23 million installed packaging units of capacity, producing solid, liquid, and semisolid pharmaceutical forms including a newly inaugurated antibiotics plant (€30M investment, 2019–2022). The product portfolio spans epilepsy, Parkinson's disease, cardiometabolic, respiratory, musculoskeletal, and antibiotic therapy areas, with a development pipeline anchored by BIA 28-6156 (pariceract), a first-in-class allosteric activator of beta-glucocerebrosidase in Phase 2b for GBA1-associated Parkinson's disease, and zamicastat for pulmonary arterial hypertension.

BIAL is led by CEO António Portela (fourth-generation family leadership) and Chairman António Horta-Osório, and maintains strategic alliances with patient associations, academic researchers, and industry partners. The company has increasingly extended into rare diseases and new modalities since 2023, established a US biotech subsidiary in 2020 (BIAL Biotech Investments Inc., Cambridge, MA), secured FDA manufacturing approval in 2024, and invested in Biovance Capital's €57M life-sciences fund as part of a broader ecosystem-buildout strategy. Ownership remains concentrated in the founding Portela family, and the company is not publicly listed.

Name

BIAL

Legal name

BIAL - Portela & Cª. S.A.

Website

https://bial.com

Company type

Private

Founded year

1924

Operating status

Operating

Headcount range

501–1,000 employees

Short description

BIAL is a privately-held, family-owned Portuguese pharmaceutical company founded in 1924 that discovers, develops, and commercializes proprietary prescription medicines focused on neurosciences and rare diseases, operating across 15 countries with two approved CNS drugs and a Phase 2b pipeline.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Prescription pharmaceuticals
• Neuroscience drug development
• Rare disease therapeutics
• Specialty pharmaceutical manufacturing
• Clinical research pipeline

Headquarters

HQ city

Coronado

HQ country

Portugal

HQ region

Europe

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: BIAL develops and commercializes its own proprietary medications, generating revenue through direct sales of prescription pharmaceuticals across multiple therapeutic areas including neurosciences, cardiometabolic, respiratory, musculoskeletal, and antibiotics.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

BIAL is an international pharmaceutical company that discovers, develops, manufactures, and commercializes proprietary prescription medicines, with a focus on neurosciences, cardiometabolic, respiratory, musculoskeletal, and infectious disease therapeutics. Its approved commercial products include the antiepileptic Acetato de Eslicarbazepina (Zebinix/Aptiom) and the Parkinson's disease treatment Opicapona (Ongentys), supported by an R&D pipeline spanning GBA1-Parkinson's disease and pulmonary arterial hypertension, plus a Trofa manufacturing facility with FDA approval.

Product overview

BIAL is a family-owned Portuguese pharmaceutical company with over 100 years of history, dedicated to patient well-being. The company operates as an international innovative pharmaceutical enterprise that develops and licenses its own medicines. BIAL's product portfolio consists of proprietary prescription medications, primarily in neuroscience and rare diseases. The core commercial products include Acetato de Eslicarbazepina (marketed as Zebinix in Europe and Aptiom in the US) for epilepsy, and Opicapona (marketed as Ongentys) for Parkinson's disease motor symptoms. The company maintains a research and development pipeline across multiple therapeutic candidates including BIA 28-6156 for GBA1-associated Parkinson's disease, along with other compounds in neuroscience and rare diseases. BIAL also operates Bialive, a digital health platform providing educational content for healthcare professionals and patients.

Differentiator

Problem solved

Functional benefit

Brands

• Bialive: Digital platform providing health information for healthcare professionals, patients, caregivers and general public, containing content developed by doctors and other health professionals
• Bialive Epilepsy
• Bialive Parkinson

Products and services

• Acetato de Eslicarbazepina (Zebinix/Aptiom) A once-daily third-generation antiepileptic from the dibenzazepine family that acts as a competitive voltage-gated sodium channel blocker and does not metabolize to carbamazepine-10,11-epoxide, offering a more favorable adverse-event profile. Approved as adjunctive therapy and monotherapy for partial-onset seizures in adults (and children, where approved), prescribed by neurologists and epilepsy specialists.
• Opicapona (Ongentys) A once-daily selective and reversible catechol-O-methyltransferase (COMT) inhibitor that increases plasma L-dopa levels when administered with L-dopa and a DOPA decarboxylase inhibitor (DDCI). Used as adjunctive therapy for Parkinson's disease patients with end-of-dose motor fluctuations, prescribed by neurologists and movement disorder specialists.
• Bialive digital health information platform A digital platform, accessible at bial.com/bialive, providing therapeutic-area content for healthcare professionals (with restricted registration), patients, caregivers, and the general public across BIAL's therapeutic areas including neurology, with specialized sub-platforms for epilepsy and Parkinson's disease.

Quantifiable outcome

• Phase 2b ACTIVATE study enrolled 273 genetically confirmed GBA-PD patients across 85 clinical sites in 11 countries over approximately 18 months with strong patient retention.
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Parkinson's EuropecoreStrategic or Co-development Partner · 10 April 2026Partnership with Parkinson's Europe to develop and launch the 'Dialogues with Parkinson's' year-long awareness and education campaign for World Parkinson's Day 2026. Campaign addresses early-onset Parkinson's symptoms, OFF episodes, and aims to improve communication between patients, caregivers, and healthcare professionals.
• International Academic and Research InstitutionscoreStrategic or Co-development PartnerBIAL collaborates actively with researchers and scientists from universities, industry partners, and research centers to develop new drugs, particularly in neurosciences and rare diseases. The company maintains partnerships in rare diseases including monogenic epilepsy and neurodegenerative diseases.
• Patient Associations and Advocacy GroupscoreStrategic or Co-development PartnerStrategic partnerships with patient associations and advocacy groups as part of rare disease program, working to find tailored therapeutic solutions for patients with rare diseases.
• Pharmaceutical and Biotech CompaniescoreStrategic or Co-development PartnerBIAL maintains partnerships with pharmaceutical and biotech companies for its rare diseases strategic area, collaborating on drug development programs.
• Licensing Partners for OpicaponacoreChannel Partner/ Reseller/ DistributorOpicapona licensed to commercialization partners: Japan (2013), USA and Canada (2017), China and South Korea (2018). These partners handle local regulatory approvals and commercialization.
• Licensing Partners for Acetato de EslicarbazepinacoreChannel Partner/ Reseller/ DistributorAcetato de eslicarbazepina licensed to commercialization partners: USA and Canada (2007), European markets (2009), South Korea (2018). Partners handle local commercialization and regulatory activities.
• EFPIA (European Federation of Pharmaceutical Industries and Associations)coreOthersBIAL is a member of EFPIA, recognizing the group's commitment to Research and Development. As a member, BIAL complies with EFPIA Code of Practice and discloses Value Transfers to Healthcare Professionals and Healthcare Organizations through the INFARMED electronic platform.
• United Nations Global CompactminorOthersBIAL is a signatory of the UN Global Compact, an international pact promoting sustainable economic development, combining companies, governments, and civil society.
• EARA - Association for Animal Research TransparencyminorOthersBIAL is a signatory of the Agreement for Transparency on Animal Research in Portugal, supported by the scientific community in collaboration with the European Association for Animal Research (EARA) to promote openness and transparency about animal use in biomedical research.
• EPIS - Empresários Pela Inclusão SocialminorOthersBIAL is a member of EPIS, an association focused on education, particularly combating school failure and dropout rates.

Scale indicators6 records

Recent moves11 records

Expansion highlights5 records

Regional players

• Almirall: Spanish specialty pharma with European commercial footprint in dermatology and CNS; comparable Iberian-heritage mid-cap specialty model even though direct product overlap is limited.

Direct peers

• H. Lundbeck: Danish pure-play neuroscience company with Parkinson's and psychiatry assets; most directly comparable to BIAL's disease-area focus on CNS disorders.
• Jazz Pharmaceuticals: Specialty pharma with a CNS/neurology franchise (Xywav, Epidiolex) and rare-disease exposure; comparable mid-sized specialty model with heavy R&D and licensing leverage.
• Supernus Pharmaceuticals: US specialty pharma focused on CNS products for epilepsy (Trokendi XR, Oxtellar XR) and Parkinson's (Apokyn), closely mirroring BIAL's therapeutic mix.
• UCB SA: Belgian specialty pharma with a leading epilepsy franchise (Vimpat/lacosamide, Keppra) and CNS focus; competes directly with BIAL in antiepileptics and shares the European mid-cap neuroscience profile.
• SK Biopharmaceuticals: Korean pharma whose lead asset (cenobamate) targets the same partial-onset seizure segment as eslicarbazepine acetate; epilepsy-focused competitor with global licensing ambitions.

Broad incumbents

• Eisai: Japanese pharma with Parkinson's (istradefylline/Equfina) and Alzheimer's franchises; competes with BIAL in Parkinson's therapy alongside partner-driven launches of opicapone.
• Kyowa Kirin: Japanese specialty pharma built around rare disease and CNS biologics; serves as a model for BIAL's stated strategic expansion into rare diseases and novel modalities.
• Ipsen: French specialty pharma with neurology, rare disease and oncology assets; overlap on rare disease strategy and CNS franchise breadth.
• Recordati: Italian specialty pharma with rare disease and CNS franchises, broader portfolio scale than BIAL but similar European mid-cap identity and family-influenced history.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/bial.farmaceutica

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries10 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIAL